Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5

BACKGROUND: Therapeutic resistance and tumor recurrence are two major hurdles in the treatment of pancreatic ductal adenocarcinoma. Recent findings suggest that both of these attributes are associated with a small subset of pancreatic tumor initiating cancer stem cells (CSCs). Here, we demonstrate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Eng, Jason W.-L., Mace, Thomas A., Sharma, Rohit, Twum, Danielle Y. F., Peng, Peng, Gibbs, John F., Pitoniak, Rosemarie, Reed, Chelsey B., Abrams, Scott I., Repasky, Elizabeth A., Hylander, Bonnie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915140/
https://www.ncbi.nlm.nih.gov/pubmed/27330806
http://dx.doi.org/10.1186/s40425-016-0136-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915140/
https://www.ncbi.nlm.nih.gov/pubmed/27330806
http://dx.doi.org/10.1186/s40425-016-0136-y

Ejemplares similares